A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
Completed · Phase 1
Conditions studied: Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
In brief
This was an open-label, multi-center, FIH study with a single ascending dose (SAD) design that assessed the safety, tolerability and pharmacokinetics (PK) of a single IVT dose of MHU650 in up to 24 participants with macular edema.
Key facts
- Study ID
- NCT04635800
- Run by
- Novartis Pharmaceuticals
- People needed
- 21
- Starts
- 2020-12-10
- Expected to finish
- 2022-05-24
- Last updated by the study team
- 2025-05-18
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Huntington Beach, California, United States
- Novartis Investigative Site — Honolulu, Hawaii, United States
- Novartis Investigative Site — Hagerstown, Maryland, United States
- Novartis Investigative Site — Austin, Texas, United States
- Novartis Investigative Site — Houston, Texas, United States
- Novartis Investigative Site — Arecibo, Puerto Rico
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.